Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention

Q: Who can participate in NCT04937699?

Eligibility for this trial depends on the specific inclusion and exclusion criteria set by the sponsor. The plain-English summary above translates the most important criteria into accessible language; the official clinical text is preserved in the collapsible section underneath. Whether you fit any specific trial is a medical decision your doctor needs to confirm — bring the trial information to your treating physician for a full review against your medical history.

Q: How do I contact the trial site for NCT04937699?

Contact information registered with ClinicalTrials.gov is shown in the sidebar of this page. Before reaching out, confirm with your treating physician that this trial is appropriate for your situation. The trial site will then walk you through the screening process to determine final eligibility.

Q: Is participating in a clinical trial safe?

Clinical trials in the United States are regulated by the FDA and overseen by Institutional Review Boards (IRBs) that review the protocol for safety. Risk varies by trial — Phase 1 studies test new treatments in humans for the first time, while Phase 3 trials use treatments that have already passed earlier safety screening. The informed consent document for any specific trial details the known risks and what to expect. Discuss those risks with your physician before deciding whether to participate.

Q: Where can I verify the data on this page?

Every detail on this page comes directly from the ClinicalTrials.gov API. Click "View on ClinicalTrials.gov" in the sidebar to see the official, unmodified record. The federal record is always authoritative; this page is a structured presentation with a plain-English eligibility translation. For background on how clinical trials are regulated, see the FDA drug approval process documentation.

Efficacy and Safety of Sequential Monotherapy of Ticagrelor and Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention With Acute Coronary Syndrome

Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention (NCT04937699) is a Phase 4 interventional studying Acute Coronary Syndrome and Percutaneous Coronary Intervention, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. RECRUITING as of the most recent ClinicalTrials.gov update. Talk to your doctor before contacting the trial site.

About This Trial

The MATE study is a randomized, multicenter, open-label, investigator-initiated clinical trial aimed to evaluate efficacy and safety of sequential monotherapy of ticagrelor and clopidogrel in patients with acute coronary syndrome (ACS) after coronary intervention. Standard DAPT of aspirin plus ticagrelor will be given for the first 1 month after PCI. After 1 month, event-free subjects will be randomized at 1:1 ratio into receiving standard DAPT (DAPT) until 12months , or switch to ticagrelor monotherapy for another 5 months , and further de-escalated to monotherapy of clopidogrel for the last 6 months(SAPT).

What Stage of Research Is This?

Phase 4 studies happen after a treatment has been approved by the FDA. They monitor long-term safety, real-world effectiveness, and any rare side effects that only emerge in larger populations over longer periods. Phase 4 results sometimes lead to label changes, additional warnings, or — rarely — withdrawal of approval.

This trial is currently recruiting participants. The sponsor has registered the study with ClinicalTrials.gov as actively enrolling, which means new applicants who meet the eligibility criteria can be considered for screening. Trial status can change between updates — confirm current recruiting status with the study contact before traveling for a screening visit.

Target enrollment of 2,690 participants makes this one of the larger Acute Coronary Syndrome trials currently registered. Trials at this scale are typically global, run across many sites, and designed to generate the definitive evidence package for an FDA approval submission or a label expansion.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Age 18-80 years old; 2. Acute coronary syndrome was diagnosed upon admission; 3. Administered ticagrelor for at least 30 days after successful PCI with implantation of a current-generation drug-eluting stent(s) 4. Agree to the study protocol and the schedule of clinical follow-up, and provides informed, written consent Who Should NOT Join This Trial: 1. Implanted with first-generation DES or bioabsorbable stent(s) during hospitalization; 2. Patients with active pathological bleeding (such as peptic ulcer or intracranial hemorrhage); 3. History of intracranial hemorrhage, intracranial neoplasms, intracranial vascular malformations or hemangioma 4. High potential risk of major bleeding, such as acute or chronic gastrointestinal ulcers or other gastrointestinal diseases, alignant tumors, etc.; 5. Thrombolytic therapy within 24 hours of index PCI; 6. Planned coronary revascularization (surgical or percutaneous) within 30 days; 7. Allergic to ticagrelor, clopidogrel or aspirin and any excipients; 8. Inability to tolerate 12-month DAPT (ticagrelor+aspirin) for any reason; 9. Cardiogenic shock or hemodynamic instability; 10. Diagnosed as active hepatitis or liver cirrhosis upon admission; 11. Suffer from a known serious progressive disease (e.g. progressive cancer, chronic obstructive lung disease, etc.;) or estimated survival time\<12 months ; 12. Platelet count\<100000 /mm3; 13. Dialysis-dependent renal failure； 14. Required use of oral anticoagulation (warfarin or other factor II or factor X inhibitors); 15. Pregnant or plan to be pregnant within 1 year; 16. Any condition that may interfere with any study procedures, such as dementia, immobility, alcohol use, etc; 17. Participating in any other clinical trial of an investigational drug or device that has not met its primary endpoint. Always talk to your doctor about whether this trial is right for you.

These are translations of the protocol\'s inclusion and exclusion criteria, simplified for patients and caregivers. The original clinical text appears below. Eligibility is ultimately confirmed by the trial site\'s screening process — this summary is a starting point for a conversation with your doctor, not a final determination.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: 1. Age 18-80 years old; 2. Acute coronary syndrome was diagnosed upon admission; 3. Administered ticagrelor for at least 30 days after successful PCI with implantation of a current-generation drug-eluting stent(s) 4. Agree to the study protocol and the schedule of clinical follow-up, and provides informed, written consent Exclusion Criteria: 1. Implanted with first-generation DES or bioabsorbable stent(s) during hospitalization; 2. Patients with active pathological bleeding (such as peptic ulcer or intracranial hemorrhage); 3. History of intracranial hemorrhage, intracranial neoplasms, intracranial vascular malformations or hemangioma 4. High potential risk of major bleeding, such as acute or chronic gastrointestinal ulcers or other gastrointestinal diseases, alignant tumors, etc.; 5. Thrombolytic therapy within 24 hours of index PCI; 6. Planned coronary revascularization (surgical or percutaneous) within 30 days; 7. Allergic to ticagrelor, clopidogrel or aspirin and any excipients; 8. Inability to tolerate 12-month DAPT (ticagrelor+aspirin) for any reason; 9. Cardiogenic shock or hemodynamic instability; 10. Diagnosed as active hepatitis or liver cirrhosis upon admission; 11. Suffer from a known serious progressive disease (e.g. progressive cancer, chronic obstructive lung disease, etc.;) or estimated survival time\<12 months ; 12. Platelet count\<100000 /mm3; 13. Dialysis-dependent renal failure； 14. Required use of oral anticoagulation (warfarin or other factor II or factor X inhibitors); 15. Pregnant or plan to be pregnant within 1 year; 16. Any condition that may interfere with any study procedures, such as dementia, immobility, alcohol use, etc; 17. Participating in any other clinical trial of an investigational drug or device that has not met its primary endpoint.

Treatments Being Tested

DRUG

Standard-DAPT of Ticagrelor plus aspirin

Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects continue for another 11 months

DRUG

Sequential monotherapy of Ticagrelor and clopidogrel

Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects switch to ticagrelor 90mg bid for 5 months; then clopidogrel 75mg qd, for another 6 months.

Locations (1)

Trial sites listed on ClinicalTrials.gov for this study. Site activation status can vary — confirm with the specific site before traveling for a screening visit.

2nd Affiliated Hospital, School of Medicine at Zhejiang University

Hangzhou, Zhejiang, China

How to Talk to Your Doctor About This Trial

Bring the printable summary of this trial — including the NCT ID (NCT04937699), the sponsor (Second Affiliated Hospital, School of Medicine, Zhejiang University), and the key eligibility criteria — to your next appointment. Your doctor can review the inclusion and exclusion criteria against your medical history, lab values, and current treatments to assess whether you are likely to qualify. They can also help you weigh whether trial participation makes sense alongside your existing care plan.

Useful questions to walk through together: What does the trial protocol require beyond standard care? How long is the active treatment phase, and how long is follow-up? Are there study visits at sites I can reach? Who pays for the trial-specific procedures, and who pays for standard-of-care portions? See our 25 questions to ask about clinical trials guide for a more complete checklist.

Authoritative Sources

The official record for this trial lives on ClinicalTrials.gov — the federal registry maintained by the National Library of Medicine at NIH. For background on how this trial fits into the FDA approval pathway, see the FDA drug approval process. For oncology-specific guidance for patients considering trials, the National Cancer Institute publishes patient-oriented overviews. International trial registries are aggregated by the WHO ICTRP.

Frequently Asked Questions

What is the NCT04937699 clinical trial studying?

Who can participate in NCT04937699?

Eligibility for this trial depends on the specific inclusion and exclusion criteria set by the sponsor. The plain-English summary above translates the most important criteria into accessible language; the official clinical text is preserved in the collapsible section underneath. Whether you fit any specific trial is a medical decision your doctor needs to confirm — bring the trial information to your treating physician for a full review against your medical history.

How do I contact the trial site for NCT04937699?

Contact information registered with ClinicalTrials.gov is shown in the sidebar of this page. Before reaching out, confirm with your treating physician that this trial is appropriate for your situation. The trial site will then walk you through the screening process to determine final eligibility.

Is participating in a clinical trial safe?

Clinical trials in the United States are regulated by the FDA and overseen by Institutional Review Boards (IRBs) that review the protocol for safety. Risk varies by trial — Phase 1 studies test new treatments in humans for the first time, while Phase 3 trials use treatments that have already passed earlier safety screening. The informed consent document for any specific trial details the known risks and what to expect. Discuss those risks with your physician before deciding whether to participate.

Where can I verify the data on this page?

Every detail on this page comes directly from the ClinicalTrials.gov API. Click "View on ClinicalTrials.gov" in the sidebar to see the official, unmodified record. The federal record is always authoritative; this page is a structured presentation with a plain-English eligibility translation. For background on how clinical trials are regulated, see the FDA drug approval process documentation.

How This Page Is Built

Every field on this page is pulled directly from the ClinicalTrials.gov API v2 — no estimates, no proxies. The plain-English eligibility translation is generated from the original protocol text and reviewed for fidelity to the underlying clinical criteria. The original clinical text remains visible in the collapsible section above so users and clinicians can verify the translation. Read the full methodology for the data pipeline and known limitations.

Source: ClinicalTrials.gov API v2 record for NCT04937699. Maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. NCT04937699. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-05-08 · Data from ClinicalTrials.gov.